Abstract
Assays based on high-performance liquid chromatography (HPLC) and liquid chromatography tandem mass spectrometry (LC–MSn) have been developed and validated for the determination and metabolite identification of the bidesmosidic triterpenoid saponin, BTS-1 (3-O-β-d-galactopyranosyl-(1→2)-[β-d-xylopyranosyl-(1→3)]-β-d-glucuronopyranosyl gypsogenin 28-O-α-l-arabinopyranosyl-(1→3)-β-d-xylopyranosyl-(1→4)-α-l-rhamnopyranosyl-(1→2)-β-d-fucopyranoside), in rat plasma. The assay was successfully applied to a pharmacokinetic study in rats given a single oral dose of BTS-1 (400mg/kg). The results indicated that the compound was rapidly absorbed (Tmax=1.28±0.29h, Cmax=37.4±5.6µg/mL) and slowly eliminated (t1/2=13.2±6.6h). In addition, secondary glycosides and aglycones of BTS-1 were detected and identified. Since these metabolites are known to be active α-glucosidase inhibitors, they probably play an important role in mediating the pharmacological effects of the saponin.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
